Mark Rubinstein to Mice, Transgenic
This is a "connection" page, showing publications Mark Rubinstein has written about Mice, Transgenic.
Connection Strength
0.425
-
IL-2Ra mediates temporal regulation of IL-2 signaling and enhances immunotherapy. Sci Transl Med. 2015 Oct 28; 7(311):311ra170.
Score: 0.105
-
G-CSF/anti-G-CSF antibody complexes drive the potent recovery and expansion of CD11b+Gr-1+ myeloid cells without compromising CD8+ T cell immune responses. J Hematol Oncol. 2013 Oct 01; 6:75.
Score: 0.091
-
Transfer of TCR genes into mature T cells is accompanied by the maintenance of parental T cell avidity. J Immunol. 2003 Feb 01; 170(3):1209-17.
Score: 0.043
-
Thioredoxin-1 improves the immunometabolic phenotype of antitumor T cells. J Biol Chem. 2019 06 07; 294(23):9198-9212.
Score: 0.033
-
Molecular Programming of Tumor-Infiltrating CD8+ T Cells and IL15 Resistance. Cancer Immunol Res. 2016 09 02; 4(9):799-811.
Score: 0.028
-
Lack of p53 Augments Antitumor Functions in Cytolytic T Cells. Cancer Res. 2016 09 15; 76(18):5229-5240.
Score: 0.028
-
Effect of administration timing of postchemotherapy granulocyte colony-stimulating factor on host-immune cell recovery and CD8+ T-cell response. J Immunotoxicol. 2016 11; 13(6):784-792.
Score: 0.028
-
The lymphopenic environment of CD132 (common gamma-chain)-deficient hosts elicits rapid homeostatic proliferation of naive T cells via IL-15. J Immunol. 2008 Apr 15; 180(8):5320-6.
Score: 0.016
-
Interleukin-15/interleukin-15R alpha complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells. Cancer Res. 2008 Apr 15; 68(8):2972-83.
Score: 0.016
-
Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells. J Immunother. 2007 Jan; 30(1):40-53.
Score: 0.014
-
Paracrine release of IL-12 stimulates IFN-gamma production and dramatically enhances the antigen-specific T cell response after vaccination with a novel peptide-based cancer vaccine. J Immunol. 2004 May 01; 172(9):5159-67.
Score: 0.012
-
Mechanisms of enhanced antigen-specific T cell response following vaccination with a novel peptide-based cancer vaccine and systemic interleukin-2 (IL-2). Vaccine. 2003 Jun 02; 21(19-20):2318-28.
Score: 0.011